Migdal Insurance & Financial Holdings Ltd. Purchases New Shares in Regeneron Pharmaceuticals, Inc. $REGN

Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 2nd quarter, HoldingsChannel reports. The firm purchased 59 shares of the biopharmaceutical company’s stock, valued at approximately $31,000.

Several other large investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in Regeneron Pharmaceuticals by 1.3% in the first quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock valued at $5,966,767,000 after acquiring an additional 121,545 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Regeneron Pharmaceuticals by 4.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company’s stock valued at $1,379,467,000 after acquiring an additional 89,579 shares in the last quarter. Amundi boosted its holdings in Regeneron Pharmaceuticals by 3.4% in the first quarter. Amundi now owns 1,603,901 shares of the biopharmaceutical company’s stock valued at $979,794,000 after acquiring an additional 52,166 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Regeneron Pharmaceuticals by 18.0% in the first quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company’s stock valued at $724,984,000 after acquiring an additional 174,056 shares in the last quarter. Finally, American Century Companies Inc. boosted its holdings in Regeneron Pharmaceuticals by 2.1% in the first quarter. American Century Companies Inc. now owns 722,467 shares of the biopharmaceutical company’s stock valued at $458,211,000 after acquiring an additional 14,921 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $652.91 on Thursday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $935.86. The business has a 50-day simple moving average of $579.44 and a two-hundred day simple moving average of $564.03. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.82. The firm has a market cap of $69.20 billion, a price-to-earnings ratio of 15.63, a price-to-earnings-growth ratio of 2.04 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. During the same quarter in the previous year, the firm earned $12.46 EPS. Regeneron Pharmaceuticals’s revenue was up .9% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Thursday, November 20th will be given a $0.88 dividend. The ex-dividend date of this dividend is Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 8.43%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on REGN. Cantor Fitzgerald boosted their target price on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a report on Wednesday. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 14th. Bank of America boosted their target price on shares of Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the company an “underperform” rating in a report on Wednesday. Morgan Stanley dropped their target price on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. Finally, Rothschild & Co Redburn initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday, August 14th. They issued a “buy” rating and a $890.00 price target on the stock. Three analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $813.78.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.